amitriptyline has been researched along with Child Development Disorders, Pervasive in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Child Development Disorders, Pervasive: Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatti, I | 1 |
| Thome, A | 1 |
| Smith, PO | 1 |
| Cook-Wiens, G | 1 |
| Yeh, HW | 1 |
| Gaffney, GR | 1 |
| Hellings, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amitriptyline for Repetitive Behaviors in Children and Adolescents With Autism Spectrum Disorders[NCT04725383] | Phase 3 | 30 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for amitriptyline and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
A retrospective study of amitriptyline in youth with autism spectrum disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amitriptyline; Atomoxetine Hydrochloride; Child; Child Dev | 2013 |